Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

Completed · Phase 2

Conditions studied: Lung Cancer, Malignant Mesothelioma, Metastatic Cancer, Thymoma and Thymic Carcinoma

In brief

RATIONALE: Radiofrequency ablation uses high-frequency electric current to kill tumor cells. CT-guided radiofrequency ablation may be effective treatment for lung cancer. PURPOSE: Phase II trial to study the effectiveness of radiofrequency ablation in treating patients who have refractory or advanced lung cancer.

Key facts

Study ID

NCT00024076

Run by

Jonsson Comprehensive Cancer Center

People needed

30

Starts

2000-05-01

Last updated by the study team

2020-08-03

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of a primary or secondary intrathoracic malignancy
• Any cell type or origin
• Involving the intrapulmonary, mediastinal, or pleural/chest wall
• Inoperable primary or metastatic cancer to the lung
• Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy, or radiotherapy)
• Single or multiple lesions that are non-contiguous with vital structures or organs such as:
• Trachea
• Heart
• Aorta
• Great vessels
• Esophagus
• Less than 5 cm in largest dimension
• Accessible via percutaneous transthoracic route
• Hepatic:
• Coagulation profile normal

Where it is running

• Jonsson Comprehensive Cancer Center, UCLA — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.